Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTIH Study of GSK2646264 in Healthy, Cold Urticaria, and Chronic Spontaneous Urticaria Subjects
NCT02424799Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GSK2646264 in Cold urticaria (CU) and chronic spontaneous urticaria (CSU) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs), Number of Participants With AEs and SAEs Defined by Severity and 6 more. Started Nov 2014; status: completed.
02
Drugs
GSK2646264
03
Conditions
Cold urticaria (CU)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02424799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424799.